Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-08-01
|
| Series: | Vaccine: X |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136223000487 |
| _version_ | 1797752944078094336 |
|---|---|
| author | Xavier Sáez-Llorens Claudio Lanata Elaine Aranguren Carlos R. Celis Rubelio Cornejo Rodrigo DeAntonio Lucie Ecker Diegi Garrido Ana I. Gil Marina Gonzales Morgan Hess-Holtz Geert Leroux-Roels Helga Junker Sarah-Katharina Kays Sven D. Koch Sandra Lazzaro Philipp Mann Gianluca Quintini Barkha Srivastava Dominik Vahrenhorst Philipp von Eisenhart-Rothe Olaf-Oliver Wolz Lidia Oostvogels |
| author_facet | Xavier Sáez-Llorens Claudio Lanata Elaine Aranguren Carlos R. Celis Rubelio Cornejo Rodrigo DeAntonio Lucie Ecker Diegi Garrido Ana I. Gil Marina Gonzales Morgan Hess-Holtz Geert Leroux-Roels Helga Junker Sarah-Katharina Kays Sven D. Koch Sandra Lazzaro Philipp Mann Gianluca Quintini Barkha Srivastava Dominik Vahrenhorst Philipp von Eisenhart-Rothe Olaf-Oliver Wolz Lidia Oostvogels |
| author_sort | Xavier Sáez-Llorens |
| collection | DOAJ |
| first_indexed | 2024-03-12T17:11:35Z |
| format | Article |
| id | doaj.art-b348038516694a90b653418856f6e575 |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-03-12T17:11:35Z |
| publishDate | 2023-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-b348038516694a90b653418856f6e5752023-08-06T04:38:10ZengElsevierVaccine: X2590-13622023-08-0114100307Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]Xavier Sáez-Llorens0Claudio Lanata1Elaine Aranguren2Carlos R. Celis3Rubelio Cornejo4Rodrigo DeAntonio5Lucie Ecker6Diegi Garrido7Ana I. Gil8Marina Gonzales9Morgan Hess-Holtz10Geert Leroux-Roels11Helga Junker12Sarah-Katharina Kays13Sven D. Koch14Sandra Lazzaro15Philipp Mann16Gianluca Quintini17Barkha Srivastava18Dominik Vahrenhorst19Philipp von Eisenhart-Rothe20Olaf-Oliver Wolz21Lidia Oostvogels22Cevaxin, The Panama Clinic, Panama City, Panama; Corresponding author.Instituto de Investigación Nutricional, Lima, PeruCevaxin, The Panama Clinic, Panama City, PanamaInstituto de Investigación Nutricional, La Molina, PeruInstituto de Investigación Nutricional, Lima, PeruCevaxin, The Panama Clinic, Panama City, PanamaInstituto de Investigación Nutricional, Lima, PeruCevaxin, The Panama Clinic, Panama City, PanamaInstituto de Investigación Nutricional, La Molina, PeruCureVac AG, Tübingen, GermanyCevaxin, The Panama Clinic, Panama City, PanamaGhent University Hospital, Ghent, BelgiumCureVac AG, Frankfurt, GermanyGhent University Hospital, Ghent, BelgiumCureVac AG, Tübingen, GermanyCureVac AG, Tübingen, GermanyCureVac AG, Frankfurt, GermanyCureVac AG, Tübingen, GermanyCureVac AG, Tübingen, GermanyCureVac AG, Tübingen, GermanyCureVac AG, Tübingen, GermanyCureVac AG, Tübingen, GermanyCureVac AG, Frankfurt, Germanyhttp://www.sciencedirect.com/science/article/pii/S2590136223000487 |
| spellingShingle | Xavier Sáez-Llorens Claudio Lanata Elaine Aranguren Carlos R. Celis Rubelio Cornejo Rodrigo DeAntonio Lucie Ecker Diegi Garrido Ana I. Gil Marina Gonzales Morgan Hess-Holtz Geert Leroux-Roels Helga Junker Sarah-Katharina Kays Sven D. Koch Sandra Lazzaro Philipp Mann Gianluca Quintini Barkha Srivastava Dominik Vahrenhorst Philipp von Eisenhart-Rothe Olaf-Oliver Wolz Lidia Oostvogels Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] Vaccine: X |
| title | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_full | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_fullStr | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_full_unstemmed | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_short | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_sort | corrigendum to safety and immunogenicity of mrna lnp covid 19 vaccine cvncov in latin american adults a phase 2 randomized study vaccine x 11 2022 100189 |
| url | http://www.sciencedirect.com/science/article/pii/S2590136223000487 |
| work_keys_str_mv | AT xaviersaezllorens corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT claudiolanata corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT elainearanguren corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT carlosrcelis corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT rubeliocornejo corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT rodrigodeantonio corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT lucieecker corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT diegigarrido corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT anaigil corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT marinagonzales corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT morganhessholtz corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT geertlerouxroels corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT helgajunker corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT sarahkatharinakays corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT svendkoch corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT sandralazzaro corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT philippmann corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT gianlucaquintini corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT barkhasrivastava corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT dominikvahrenhorst corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT philippvoneisenhartrothe corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT olafoliverwolz corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT lidiaoostvogels corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 |